Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02712320 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
A Phase 3 study, sponsored by Foresee Pharmaceuticals Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT02712320: Completed Phase 3 study, sponsored by Foresee Pharmaceuticals Co..
NCT02712320 is a Phase 3 study that has completed, run by Foresee Pharmaceuticals Co.. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02712320, a Phase 3 study, has completed, sponsored by Foresee Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.
Primary Outcome
Evaluate the incidence of adverse events, drug-related adverse events, and serious adverse events
Interventions
- DRUG LMIS 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-12-19 |
| Phase | Phase 3 |
What the finished NCT02712320 record still lists
NCT02712320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which LMIS 50 mg is the first listed.
NCT02712320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02712320 about?
NCT02712320 is a clinical study titled "Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg". This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX w...
What is the current status of trial NCT02712320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2016-02. Estimated completion is 2017-12-19.
What interventions are being tested in trial NCT02712320?
The interventions under investigation include: LMIS 50 mg (DRUG).
Who is sponsoring clinical trial NCT02712320?
This trial is sponsored by Foresee Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02712320's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia